AI assistant
Sending…
Lexaria Bioscience Corp. — Director's Dealing 2009
Mar 7, 2009
34983_dirs_2009-03-06_69f0e525-a6c1-4f3b-aba2-6091330b73e1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LEXARIA CORP. (LXRA)
CIK: 0001348362
Period of Report: 2009-03-04
Reporting Person: BUNKA CHRISTOPHER (Director, Chariman/CEO/President/CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2009-03-04 | Stock Options | $0.12 | A | 400000 | Acquired | 2011-07-20 | Common Shares (400000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Shares | 863600 | Direct |
| Common Shares | 1364450 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants | $0.6 | 2011-04-26 | Common Shares (1166800) | 1166800 | Indirect |
| Stock Optionns | $0.8 | 2011-04-26 | Common Shares (400000) | 400000 | Direct |
Footnotes
F1: Chris Bunka is the sole owner of CAB Financial Servies Ltd.
F2: On June 19, 2007, the exercise price was reduced from $1.30.
More from Lexaria Bioscience Corp.
Interim / Quarterly Report
2026
Apr 13
Director's Dealing
2026
Mar 18
Delisting Announcement
2026
Feb 6
Regulatory Filings
2026
Jan 28
Declaration of Voting Results & Voting Rights Announcements
2026
Jan 28
Capital/Financing Update
2026
Jan 14
Delisting Announcement
2026
Jan 14
Interim / Quarterly Report
2026
Jan 13
Capital/Financing Update
2025
Dec 29
Regulatory Filings
2025
Dec 19